Cell Technologies in Immunotherapy of Cancer

Moiseyenko, Vladimir; Imyanitov, Evgeny N.; Данилова, Анна; Danilov, Alexey Olegovich; Балдуева, Ирина

doi:10.1007/978-0-387-72005-0_42

Cited by 7 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biopsy samples from solid tumor patients (n = 11) were collected and further used to develop cell culture in vitro as previously described. 48 The cells were cultured in medium containing Dulbecco's modified Eagle's medium (DMEM)/F12 (80%) (Lonza, Switzerland), fetal bovine serum (20%) (FBS, HyClone), insulin (5 μg/mL), transferrin (5 μg/mL), selenium (5 ng/mL) (Sigma-Aldrich, U.K.), 100 IU/mL penicillin, and 0.1 mg/mL streptomycin (Biolot, Russia) at 37 °C, 5% CO 2 , 100% humidity. After reaching 80%, confluent monolayer cells were reseeded at vials of 25 cm 2 in 5 mL of medium seeded 1 × 10 6 cells using 0.25% trypsin− EDTA solution (Sigma-Aldrich, U.K.).…”

Section: Methodsmentioning

confidence: 99%

Safe and Effective Delivery of Antitumor Drug Using Mesenchymal Stem Cells Impregnated with Submicron Carriers

Timin

Peltek

Zyuzin

et al. 2019

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

An important area in modern malignant tumor therapy is the optimization of antitumor drugs pharmacokinetics. The use of some antitumor drugs is limited in clinical practice due to their high toxicity. Therefore, the strategy for optimizing the drug pharmacokinetics focuses on the generation of high local concentrations of these drugs in the tumor area with minimal systemic and tissue-specific toxicity. This can be achieved by encapsulation of highly toxic antitumor drug (vincristine (VCR) that is 20–50 times more toxic than widely used the antitumor drug doxorubicin) into nano- and microcarriers with their further association into therapeutically relevant cells that possess the ability to migrate to sites of tumor. Here, we fundamentally examine the effect of drug carrier size on the behavior of human mesenchymal stem cells (hMSCs), including internalization efficiency, cytotoxicity, cell movement, to optimize the conditions for the development of carrier-hMSCs drug delivery platform. Using the malignant tumors derived from patients, we evaluated the capability of hMSCs associated with VCR-loaded carriers to target tumors using a three-dimensional spheroid model in collagen gel. Compared to free VCR, the developed hMSC-based drug delivery platform showed enhanced antitumor activity regarding those tumors that express CXCL12 (stromal cell-derived factor-1 (SDF-1)) gene, inducing directed migration of hMSCs via CXCL12 (SDF-1)/CXCR4 pathway. These results show that the combination of encapsulated antitumor drugs and hMSCs, which possess the properties of active migration into tumors, is therapeutically beneficial and demonstrated high efficiency and low systematic toxicity, revealing novel strategies for chemotherapy in the future.

show abstract

Section: Methodsmentioning

confidence: 99%

Safe and Effective Delivery of Antitumor Drug Using Mesenchymal Stem Cells Impregnated with Submicron Carriers

Timin

Peltek

Zyuzin

et al. 2019

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

“…Mononuclear cells were isolated from the collected cells from peripheral blood of GC and CRC patient by following an established method [36], [37] using Ficoll (GE Healthcare life Science, Shanghai, China). Isolated cells were suspended in RPMI 1640 medium at a concentration of 1×10 7 mL −1 and cultured in 175 cm 2 cell culture flasks at 37°C, 5% CO 2 for 2 hrs.…”

Section: Methodsmentioning

confidence: 99%

Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy with Cytokine-Induced Killer Cells Improves Survival in Gastric and Colorectal Cancer Patients

Gao

Xie

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

Gastric and colorectal cancers (GC and CRC) have poor prognosis and are resistant to chemo- and/or radiotherapy. In the present study, the prophylactic effects of dendritic cell (DC) vaccination are evaluated on disease progression and clinical benefits in a group of 54 GC and CRC patients treated with DC immunotherapy combined with cytokine-induced killer (CIK) cells after surgery with or without chemo-radiotherapy. DCs were prepared from the mononuclear cells isolated from patients using IL-2/GM-CSF and loaded with tumor antigens; CIK cells were prepared by incubating peripheral blood lymphocytes with IL-2, IFN-γ, and CD3 antibodies. The DC/CIK therapy started 3 days after low-dose chemotherapy and was repeated 3–5 times in 2 weeks as one cycle with a total of 188.3±79.8×106 DCs and 58.8±22.3×108 CIK cells. Cytokine levels in patients' sera before and after treatments were measured and the follow-up was conducted for 98 months to determine disease-free survival (DFS) and overall survival (OS). The results demonstrate that all cytokines tested were elevated with significantly higher levels of IFN-γ and IL-12 in both GC and CRC cohorts of DC/CIK treated patients. By Cox regression analysis, DC/CIK therapy reduced the risk of post-operative disease progression (p<0.01) with an increased OS (<0.01). These results demonstrate that in addition to chemo- and/or radiotherapy, DC/CIK immunotherapy is a potential effective approach in the control of tumor growth for post-operative GC and CRC patients.

show abstract

“…Patients would create CTL activity in response to SART3 antigen initiated by the DNA vaccine injection and that might bring about a breakthrough in malignant tumor treatments [15]. Recently, studies suggested that tumor vaccines combined with adjuvants [16,17] and cytokines [9] or injected directly with a form of purified expression antigen [18] possibly received a better immunological reaction. This is a good potential for further research.…”

Section: Discussionmentioning

confidence: 99%

Antitumor immunity of human SART3 gene vaccine against mouse tumor in vitro/vivo

Yang

Liu

et al. 2008

Front. Med. China

View full text Add to dashboard Cite

To determine whether squamous cell carcinoma antigen recognized by human T cell 3 (SART3) gene can induce antitumor immunity against tumor cells which express the gene, we constructed mouse tumor cells expressing human SART3 (LM8-SART3) and carried out experiments in vitro/vivo. After subcutaneous injection with SART3 gene vaccine, cytotoxic T lymphocyte (CTL) activity in vitro was measured using Cell Counting Kit-8. As for the in vivo part, C3H mice were divided into several groups. One group was challenged with tumor cells after immunity. Another group was treated with the vaccine after tumor implantation. It was found that human SART3 DNA vaccine can elicit a specific CTL reaction from the mouse splenocytes. After vaccination, tumor occurrence and tumor growth speed was reduced. The vaccine also shows activity in tumor treatment. We conclude that the human SART3 DNA vaccine can induce antitumor ability against tumor cells expressing human SART3 (LM8-SART3) in vitro/vivo which may provide new possibilities in antitumor therapy.

show abstract

Cell Technologies in Immunotherapy of Cancer

Cited by 7 publications

References 6 publications

Safe and Effective Delivery of Antitumor Drug Using Mesenchymal Stem Cells Impregnated with Submicron Carriers

Safe and Effective Delivery of Antitumor Drug Using Mesenchymal Stem Cells Impregnated with Submicron Carriers

Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy with Cytokine-Induced Killer Cells Improves Survival in Gastric and Colorectal Cancer Patients

Antitumor immunity of human SART3 gene vaccine against mouse tumor in vitro/vivo

Contact Info

Product

Resources

About